Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Revue D'Epidemiologie Et De Sante Publique
|
May 7, 2021
R Giorgi, J-M Boher,
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2001
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients
J L Pujol, J M Boher, J Grenier, et al.
British Journal of Cancer
|
July 1, 2004
Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
W Jacot, J-L Pujol, J-M Boher, et al.
Computers in Biology and Medicine
|
July 29, 2018
Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package
B Cabarrou, P Sfumato, E Leconte, et al.
British Journal of Cancer
|
April 3, 1999
Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis
J M Boher, J L Pujol, J Grenier, et al.
Computer Methods and Programs in Biomedicine
|
January 28, 2015
Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R
B Cabarrou, A Jouin, J M Boher, et al.
Computer Methods and Programs in Biomedicine
|
July 20, 2019
Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models
P Sfumato, T Filleron, R Giorgi, et al.
The British Journal of Surgery
|
December 24, 2014
Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment
F Paye, R Micelli Lupinacci, P Bachellier, et al.
Revue Des Maladies Respiratoires
|
November 7, 1998
[Neuron-specific enolase (NSE) in the surveillance of small cell cancers. An evaluation of the prognostic information using Markov's model]
J L Pujol, J M Boher, J Grenier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 7, 2017
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
P Marino, P Sfumato, F Joly, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Revue D'Epidemiologie Et De Sante Publique
|
May 7, 2021
R Giorgi, J-M Boher,
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2001
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients
J L Pujol, J M Boher, J Grenier, et al.
British Journal of Cancer
|
July 1, 2004
Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
W Jacot, J-L Pujol, J-M Boher, et al.
Computers in Biology and Medicine
|
July 29, 2018
Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package
B Cabarrou, P Sfumato, E Leconte, et al.
British Journal of Cancer
|
April 3, 1999
Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis
J M Boher, J L Pujol, J Grenier, et al.
Computer Methods and Programs in Biomedicine
|
January 28, 2015
Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R
B Cabarrou, A Jouin, J M Boher, et al.
Computer Methods and Programs in Biomedicine
|
July 20, 2019
Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models
P Sfumato, T Filleron, R Giorgi, et al.
The British Journal of Surgery
|
December 24, 2014
Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment
F Paye, R Micelli Lupinacci, P Bachellier, et al.
Revue Des Maladies Respiratoires
|
November 7, 1998
[Neuron-specific enolase (NSE) in the surveillance of small cell cancers. An evaluation of the prognostic information using Markov's model]
J L Pujol, J M Boher, J Grenier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 7, 2017
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
P Marino, P Sfumato, F Joly, et al.
Page
of 3